53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
A large-scale trial examining the effect of azithromycin on the relationship between oesophageal function and cough as evaluated by Hyfe's cough monitoring technology in respiratory disease is feasible and acceptable to patients.
This study used Hyfe's wearable cough monitor during a 7-day run in, 28-day treatment, and 14-day follow-up period in patients with chronic bronchitis.
Periods of intense coughing (termed bouts, epochs or bursts) are particularly problematic for some coughers and may not be reflected by simply counting the number of coughs per day. This study explored how varying the definition of bouts yield different impressions of cough severity.
01.10.2024
Real-time continuous cough monitoring using wearable technology is a novel technique of quantifying disease severity in patients with chronic cough. Little is known about how daily objective cough count measured by such devices correlates with subjective assessment of symptoms in cough patients.
Patients with chronic cough were monitored the Hyfe CoughMonitor for 30 consecutive days and concomitantly recorded daily cough severity scores using the Cough Visual Analogue Scale (VAS). Objective cough count data collected was recorded and correlated with daily VAS scores.
12 Patients recorded a median of 93 coughs per day (range 3-637) with a mean (SD) cough VAS score of 43mm (24mm). There was no significant association between daily cough count and daily cough VAS score in any of the patients. Scatter plots demonstrating these relationships can be visualised in Figure 1 and the Pearson correlation coefficients can be seen in Table 1.
There is no association between daily objective cough counts and daily cough VAS scores, more work is required to find the optimal endpoint for responses to treatment for chronic cough.
